2025-06-05-Jefferies-萨瓦拉公司（SVRA）_提交申请被拒似乎可以解决；将于2025年第四季度重新提交肺部疾病相关申请_8页_107kb

Savara Inc. (SVRA) Equity Research Summary

Regulatory Update

• The FDA rejected the Refuse-to-File (RTF) for molgramostim (Molbreevi) for autoimmune pulmonary alveolar proteinosis (aPAP). The rejection is viewed as potentially administrative, stemming from incomplete in-process testing.
• Management plans to meet with the FDA by July 26, 2025, and expects an update by August 25, 2025. A subsequent BLA resubmission is scheduled for Q4 2025.
• Approval timeline is now projected to mid-2026, with market potential as high as $400M+ in peak sales.

Drug Details

• Molgramostim is in development for aPAP and has shown strong Phase III data, potentially positioning it as a first-line treatment. Ongoing studies may provide longer-term outcomes.
• Supply chain improvements are noted, with Fujifilm set to provide redundant drug substance capabilities. Fujifilm's tech transfer is complete; downstream campaigns are nearing completion, supporting a higher approval likelihood.

Market Potential

• SVRA aims to reach over 1,000 diagnosed aPAP patients at launch, with an estimated 3,600 diagnosed and 3,700 undiagnosed U.S. patients, potentially growing market size through its antibody test.
• Previous patient identification has increased (from 300 in Sep 2024 to over 500 as of June 2025). Launch could drive significant revenue via high net price points (~$350K per patient).

Valuation and Rating

• Rating: BUY with a price target of $8.50 (+254% upside from current price).
• Valuation based on NPV analysis with a 90% success probability in aPAP and no biosimilar competition. Risks include regulatory delays, competition, and commercial obstacles.

Key Risks

• Regulatory Issues: FDA approval delays remain a concern, though resubmission is on track; RTF reason is deemed benign and fixable.
• Commercial: Achieving patient access and market penetration requires substantial sales efforts and capitalizing on the opportunity.
• Pipeline: molgramostim's potential as a chronic therapy could solidify its position if longer-term data is supportive. Competition from existing treatments (e.g., Leukine) also factors into U.S. launch strategy.

Analyst Certification

• Equity analysts certify that recommendations reflect personal views and are not tied to compensation.

Disclosures

• Report includes standard industry disclosures, conflicts of interest, and limitations on equity research due to potential ties with the company.